BGPT: Paper Review: Neurotrophins in Neurodevelopmental Disorders: A Narrative Review of the Literature

Explore by Goal

Quick Explanation Copied

Verdict (skeptical, evidence-weighted)

This MDPI narrative review argues that neurotrophin signaling (especially BDNF/NGF, plus NT-3, NT-4/5, and GDNF) is biologically plausible in neurodevelopmental disorders (ADHD, ASD, ID, and tic disorders) and may serve as research biomarkers/targets, while emphasizing inconsistent peripheral-biomarker findings due to assay and cohort heterogeneity .

Most useful takeaway: it repeatedly frames peripheral neurotrophins as research biomarkers whose directionality is likely context-dependent (age/sex/assay/sample type/medication), rather than a ready diagnostic test .

Long Explanation

Paper Review (visual-first): Neurotrophins in Neurodevelopmental Disorders: A Narrative Review of the Literature

Journal: Int. J. Mol. Sci. (Published 28 Aug 2025). DOI: 10.3390/ijms26178335

Scope stated by authors: ADHD, ASD, intellectual disability (including non-syndromic ID), and tic disorders; focuses on BDNF, NGF and related neurotrophins; explores biomarker and therapeutic target potential .

1) Visual: What this review emphasizes (from its own claims)

The review’s repeated structure is: (i) neurotrophin biology in development (ii) peripheral/central dysregulation summaries per disorder (iii) assay/sample-type heterogeneity as a driver of inconsistent results (iv) biomarker/target framing with explicit calls for standardization and stratified longitudinal research .

2) Visual: Effect-size example for ASD peripheral BDNF (one cited meta-analysis)

The review discusses conflicting peripheral BDNF findings in ASD and points to meta-analytic evidence. Below is one quantitative snapshot explicitly provided in the extracted dataset (JAMA Pediatrics meta-analysis): overall standardized mean difference (Hedges g) with 95% CI .

Skeptical read: even when an overall peripheral difference appears statistically detectable, the review stresses that between-study variance (assay type, sample handling, age/sex, medication, and platelets/serum vs plasma handling issues) can erode biomarker reliability .

3) Visual: Proposed neurotrophin signaling “wiring” (conceptual)

The review summarizes canonical biology: mature neurotrophins bind Trk receptors (BDNF→TrkB, NGF→TrkA, NT-3→TrkC), while proneurotrophins can signal through p75NTR with effects that can oppose mature-neurotrophin outcomes; downstream pathways include Ras/MAPK/ERK and PI3K/Akt .

Important uncertainty: the review’s conceptual wiring is canonical, but the translation to disorder-specific peripheral biomarker directions is explicitly inconsistent across studies .

4) Evidence map by disorder (what the review claims, and how confident we can be)

Disorder	Neurotrophin focus (from review)	Consistency signal (per review)	Key skeptical note
ADHD	BDNF/pro-BDNF balance; NT-3; NGF; GDNF	Mixed/variable directions; meta-analyses reported as inconsistent	Plasma vs serum, platelet storage, medication status, and EEG linkage add confounding risk
ASD	Peripheral BDNF (and pro-BDNF ratio); NT-3; SNP interactions; IGF-1 discussed as overlapping growth-factor axis	Conflicting individual studies; at least one meta-analysis reports higher peripheral BDNF	Diagnosis heterogeneity + assay heterogeneity likely dominate peripheral effects
Non-syndromic ID	Mostly BDNF	Limited and heterogeneous; one reported positive association with cognition	Sparse longitudinal/phenotyped cohorts make causal inference difficult
Tic disorders (incl. Tourette spectrum)	BDNF/NGF/GDNF; neuroimmune links	Inconclusive peripheral NGF/GDNF; genetic evidence for GDNF in TS described	Small cohort biomarkers plus genetic heterogeneity; need replication and mechanistic bridging

5) Methods critique (narrative review constraints)

The authors explicitly choose a narrative approach citing heterogeneity across study designs, ages, and biomarker measurement methods, and they state inclusion of clinical and mechanistic in vitro/preclinical work .

Blind spot risk: narrative selection can amplify “best story” bias vs systematic pre-registered inclusion; the review does not provide the reproducibility artifacts typical of systematic reviews (e.g., PRISMA flow, protocol registration) in the provided excerpt .
Heterogeneity as both reason and limitation: the same heterogeneity that motivates narrative synthesis also limits inference strength about directionality and causality .
Translation caution: the review states it explicitly marks animal/in vitro evidence and avoids extrapolating unless clearly stated; that’s a good practice, but the mechanistic “bridge” still remains uncertain without human intermediate phenotypes .

6) Therapeutic/biomarker critique (what’s plausible vs what’s proved)

The review argues that circulating neurotrophins have biological plausibility as biomarkers/targets, but emphasizes limited diagnostic utility due to overlap with controls and context dependence (age/sex/medication/activity) and recommends assay standardization plus careful distinction between pro-BDNF and mature BDNF .

Where the review’s claims are strongest

Canonical neurotrophin signaling (Trk vs p75NTR, downstream cascades) is well-established biology, and the review accurately frames it as mechanistic motivation for neurodevelopmental effects .
The review’s insistence on measurement/assay heterogeneity as a driver of inconsistent peripheral biomarker findings is consistent with its own discussion of serum vs plasma handling and pro- vs mature neurotrophin biology .

Where inference is weakest (scientific skepticism)

Biomarker → diagnosis: The review concludes peripheral biomarkers currently lack routine clinical utility because effects are small-to-moderate with substantial between-study variance and overlap with controls .
Causality: even when meta-analyses show group differences, cross-sectional peripheral biomarkers rarely establish causal direction (and the review repeatedly notes limited longitudinal data) .

7) Falsification-minded “disproof targets” (what would change the story)

A strong disconfirmation would be robust, standardized, longitudinal evidence that (i) peripheral neurotrophin differences do not track developmental trajectories within phenotypes and (ii) pro- vs mature neurotrophin measures do not add discriminative or mechanistic value beyond confounds (age, sex, medication, activity) .

8) Bottom-line synthesis (tight)

This review’s core scientific contribution is not new data; it’s a structured narrative synthesis emphasizing that neurotrophin biology is highly plausible in neurodevelopment while current peripheral biomarker evidence in ADHD/ASD/ID/tics remains inconsistent and method-sensitive, motivating standardized longitudinal stratification efforts .

Author-specific follow-ups (BGPT Author Review)

Select any author to see BGPT’s dedicated critique lens for that contributor.

Feedback:

Updated: March 25, 2026